about
A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responsesA vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II moleculesHIV-prevention science at a crossroads: advances in reducing sexual risk.Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Elimination of helminth infection restores HIV-1C vaccine-specific T cell responses independent of helminth-induced IL-10Timing of immune escape linked to success or failure of vaccination.Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infectionNew approaches to design HIV-1 T-cell vaccinesCofactors that may influence vaccine responses.Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides.Immune activation promotes evolutionary conservation of T-cell epitopes in HIV-1.Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.Receptor binding domain based HIV vaccines."Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination.Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infectionDNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challengeDeletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity.A Recombinant Adenovirus Encoding Multiple HIV-1 Epitopes Induces Stronger CD4(+) T cell Responses than a DNA Vaccine in Mice.Weighing the gold in the gold standard: challenges in HIV prevention research.Enhancement of viral escape in HIV-1 Nef by STEP vaccination.T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine.HIV-specific CD4 T cells and immune control of viral replication.Current progress in development of hepatitis C virus vaccines.Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials.A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial.The impact of viral evolution and frequency of variant epitopes on primary and memory human immunodeficiency virus type 1-specific CD8⁺ T cell responses.The STEP study provides a hint that vaccine induction of the right CD8+ T cell responses can facilitate immune control of HIV."Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown.Building on the past to define an efficient path to an HIV vaccine
P2860
Q28742853-7A22923A-99EF-4B48-A9E7-23370A123BFEQ28751663-E235383D-39B8-4974-96FB-0FB68E0CCE99Q30378142-66326D1D-92BE-49F7-A332-29F1E50D05ADQ30378897-9FBD833B-696F-4808-82E9-CC057A276EE6Q33699560-282078D2-9441-4524-BEE0-CD2BE5A5085EQ33700493-80DA927D-86CE-497D-90F3-B7CBAF6EE09CQ33828583-C5066E1C-CA34-4488-875A-4FCCB4E7BDA3Q34274849-3046F5C7-E113-4963-96D6-00711CF5EFCDQ34297930-53D9BAC0-66BF-4D98-A6F2-F2DD51F56EE4Q34428561-2C07D137-10CA-4EB2-BA8D-32336A25CFECQ34657787-E5F55781-6FFC-4111-BE34-2E15B706065AQ34673391-42CEA8AD-9FAB-4809-90EC-38EC162F45E8Q34982651-6DA4EA07-3841-448C-9B88-9FBE69E3605AQ35033862-685E227E-309C-465E-9EA0-2CF4B627E5FCQ35219438-00952C4F-24F4-4FC8-9E13-EA1EAAF9E450Q35274776-3A0FF621-5F46-4C81-AE00-19C30A86649FQ35382338-0E05A10D-E37F-4F8D-AA68-C3DD055124C6Q36024470-612C3E04-524C-43BB-A031-9F009DDB3029Q36397581-D60568C2-D80F-4A62-ACD6-5EA9592C0325Q36483435-70B53FF6-1F5A-46BA-A5DE-D702C5195E74Q36956883-8A645FD2-67D4-4F3C-BAD1-30CD7AA75C2EQ36964025-CF5B1E13-D734-43E0-B15E-0EEC355F9D45Q37312719-783937AA-935C-4C0B-897F-D33264270D66Q37333743-D12064CC-F97A-4925-B2FD-4162A18BE087Q37628515-6CE6F3E2-07F0-49FD-AE1A-E5EE47BA9DC5Q37866624-BE3007D0-A7F2-445A-BECB-F8343B5DD452Q38120201-325E2544-5498-4A50-BC0A-4DCC714E920FQ39648796-08D5BD4C-2406-44B6-B6BC-4A26711FD155Q40379142-2811AE07-C3E8-470E-BEAE-C44F7D435427Q41926056-F5C7853D-7A76-4E14-A246-753D555E4636Q41981778-81541C17-6A02-46D2-A47C-C74AF7C0D655Q42710662-69EFEF71-B371-4EBA-A84B-82EFE0338668Q51692824-229B0754-8309-4087-BA6C-7083F96CDD42Q56880573-D3F31894-5CB5-4520-9EE7-794B931B4772
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Post-step modifications for research on HIV vaccines
@en
Post-step modifications for research on HIV vaccines.
@nl
type
label
Post-step modifications for research on HIV vaccines
@en
Post-step modifications for research on HIV vaccines.
@nl
prefLabel
Post-step modifications for research on HIV vaccines
@en
Post-step modifications for research on HIV vaccines.
@nl
P2860
P1433
P1476
Post-step modifications for research on HIV vaccines
@en
P2093
James G Kublin
P2860
P356
10.1097/QAD.0B013E32830E6D6D
P407
P577
2009-01-01T00:00:00Z